Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX : to Host Virtual Investor Day on December 7, 2021

10/14/2021 | 04:05pm EST

MARIETTA, Ga., Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning at 9:00 a.m. ET. The event will focus on the Company’s musculoskeletal late-stage pipeline and advanced wound care business. Further details regarding registration, presenters and format will follow.

A live webcast will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com at the time of the event. A replay of the webcast will be available on the Company’s website following the conclusion of the event.

About MIMEDX

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact:
Jack Howarth
Investor Relations
404-360-5681
jhowarth@mimedx.com

Contact:
Hilary Dixon
Corporate & Strategic Communications
404-323-4779
hdixon@mimedx.com


Primary Logo

Source: MiMedx Group, Inc

2021 GlobeNewswire, Inc., source Press Releases

All news about MIMEDX GROUP, INC.
12/07MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
12/07MiMedx Lifts Adjusted Net Sales Outlook for FY21
MT
12/07MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
AQ
11/30MIMEDX Announces Speakers for December 7 Investor Day
AQ
11/26Top Premarket Decliners
MT
11/22MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
11/22MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference
GL
11/17Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM..
AQ
11/17Mimedx Group, Inc. Announces Publication of Peer-Reviewed Study in Facial Plastic Surge..
CI
11/02MIMEDX : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 255 M - -
Net income 2021 -20,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -40,1x
Yield 2021 -
Capitalization 817 M 817 M -
Capi. / Sales 2021 3,21x
Capi. / Sales 2022 2,91x
Nbr of Employees 735
Free-Float 96,6%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 7,36 $
Average target price 13,83 $
Spread / Average Target 88,0%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-25.00%817
MODERNA, INC.170.27%114 479
GILEAD SCIENCES, INC.19.55%87 368
BIONTECH SE243.27%73 106
REGENERON PHARMACEUTICALS31.46%66 402
WUXI APPTEC CO., LTD.21.75%63 075